



# **Task 2.1 - Development of Strategic Research Agenda, roadmap and priorities for research on low dose risk**

**Lead: MELODI**

**Partner: BfS, MTA-EK, DH-PHE, HMGU, IRSN, STUK, ENEA, UniPv, CEA; LTPs: CTU-FBME, CREAL, SU**

# MELODI (Multidisciplinary European Low dose Initiative)

## MELODI Working Group SRA

- **Michaela Kreuzer (Chair)**, *BfS, Germany*
- **Imre Balashazy**, *MTA-EK, Hungary*
- **Simon Bouffler**, *PHE, UK*
- **Elisabeth Cardis**, *CREAL, Spain*
- **Peter Jacob**, *HMGU, Germany*
- **Mats Harms-Ringdahl**, *SU, Sweden*
- **Jean-Rene Jourdain**, *IRSN, France*
- **Katja Kojo**, *STUK, Finland*
- **Simona Pazzaglia**, *ENEA, Italy*
- **Friedo Zölzer**, *Czech Republic*
  
- **Kevin Prise**, *UK*
- **Dietrich Averbeck**, *IRSN, France*




# **MELODI WG SRA**

## **- Activities -**

- **Annual update of the SRA**
- **Preparation of a short MELODI statement, presenting the top priorities (only in years when a call will be launched)**
- **Open consultation process via website and the MELODI workshop**
- **Updated SRA and statement are sent by the WG SRA to the MELODI Board of Directors for comments and approval**
- **Final review by the independent Scientific Committee of MELODI**

# Process of development of SRA and statement



# Task 2.1 Key activities

- The MELODI **SRA** is revised on a 5-year basis.
- During the SRA period, a **SRA-statement** is prepared annually and discussed by open consultation. This consultation will be finalized during the annual MELODI meeting. (⇒ **M2**)
- A long-term **roadmap** for research is developed by MELODI (⇒ **M16**)
- Annually, **short-term research priorities** are elaborated by MELODI.
- Providing input to Joint Programming (WP3)

# Current status of work of the WG SRA

- **Meeting of the MELODI WG SRA on 27<sup>th</sup> March 2015 in Munich**
- **Discussion on**
  - Update of SRA
  - Development of the MELODI statement
  - Development of a roadmap
- **Keeping in mind the timelines of MELODI and the CONCERT Project**

# Update of SRA

## Structure of the SRA report

1. Executive Summary
2. Importance of low dose risk research
3. SRA (3 key research questions and priorities)
4. Synergistic topics of MELODI with other platforms
5. Education and Training
6. Infrastructures
7. Research priorities
8. Feasibility and impact assessment of research priorities

# MELODI statement

## First thoughts of the WG SRA

- **Definition of one broad innovative topic, which allows the application of a multidisciplinary research group**
- **Definition of 3-5 short-term priorities for each key question** (dose response cancer, non-cancer, individual sensitivity)

### **CONCERT:**

- Provide MELODI statement end of July
- Joint priority setting meeting in September 2015
- Decision on budget balance between platforms and type of topics (broad or small) by Management Board



# Roadmap

## First thoughts of the WG SRA

- **Difficult to develop a traditional roadmap in this field, because it is not possible to estimate what can be solved in which time line for the science in MELODI**
- **Alternative:**
  - Definition of what is feasible for different dose ranges
  - Feasibility and importance assessment for the three key questions

### **CONCERT:**

- Joint roadmap and related budget allocation
- Year one: Propose a strategy for the development of a long-term roadmap